Dr. Alejandro Sayús Tranfaglia M, Nguyen DV, Hagerman R. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J.Med.Genet. 2009; 46: 266-271. 9) Bungdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK, Gross AL, Kroes RA, Moskal JR. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 2013 Apr; 38(5): 729-42. 10) Bunney B G, Bunney W E. Mechanisms of rapid antidepressant effects of sleep deprivation therapy: clock genes and circadian rhythms. Biol Psychiatry 2012;73:1164-1171. 11) Campo B, Kalinichef M, Lamberg N, El Yacoubi M, Roger Urios I, Schnaider M. et al. Caracterization of an mGlu2/3 negative modulator in rodent models of depression. J. Neurogenet. 2011; vol. 25 (4): 152-166. 12) Chaki S, Ago Y, Palucha-Paniewiera A, Matrisciano F, Pilc A. mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants. Neuropharmacology. 2013; 66:40-52. 13) Choudary PV, Moinar M, Evans SJ, Tomita H, Li JZ, Vawter MP et al. Altered cortical glutamatérgica and GABAergic signal transmission with glial involment in depression. Proc. Natl. Acad. Sci. USA. 2005; 102:15653-15658. 14) Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 1997; 37:205-37. 15) Crane GE. Cyloserine as an antidepressant agent. Am J Psychiatry.1959 May;115(11):1025-6. 16) Dagestad G, Kuipers SD, Messaoudi E, Bramham CR. Chronic fluoxetine induces region-specidfic changes in translation factor elF4E and eEF2 activity in the rat brain. Eur. Neurosci 2006; 23:2814-8. 17) Davies J, Evans RH, Francis AA, Watkins JC. Excitatory aminoacid receptors and synaptic excitation in the mammalian central nervous system. 1979. J Physiol (París) 75(6):641-54. 18) Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-ontrial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010; 67:793-802. 19) Duman RS. Depression: a case of neuronal life and death? Biol. Psychiatry 2004; 56:140-5 20) Duman RS. and Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends in Neurosciences, January 2012; Vol 35, No.1:47-56. 21) Dwivedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, Pandey GN. Modulation in activation and expression of phosphatase and tensin homolog on chromosome ten, Akt1, an 3-phosphoinositide-dependent kinase 1: further evidence demonstrating altered phosphoinositide 3-kinase signaling in postmortem brain of suicide subjects. Biol Psychiatry. 2010; 67(11):1017- 1025. 22) El Iskamdarani K.M. Electrophysiological investigations of the effects of subanesthetic dose of ketamine on monoamine systems. Thesis University of Ottawa, Institute of Mental Healt Research, Department of Cellular and Molecular Medicine Ottawa, ON, Canada. 2014. 23) Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 2013; 38:743-752. 24) Fedele E, Foster AC. An evaluation of the role of extracellular amino acids in the delayed neurodegeneration induced by quinolinic acid in the rat striatum. Neuroscience. 1993; 52:911-917. 25) Fell MJ, Witckin JM, Falcone JF, Katner JS, Peryy KW, Hart J. et. al. N-(4-((2-(trifluororomethyl)-3- hydroxy-4-(isobutyryl)phenoxy)-methyl)benzyl)- 1- methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: In vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J. Pharmacol Ther. 2011; 336:165-177. 26) Ferreira FF, Biojone C, Roca SRL, Guimaraes FS. Antidepressant-like effects of N-acetyl-L-cysteine in rats. Behav. Pharmacol. 2008; 19:747-750 2008. 27) Feyissa AM Woolverton WL, Miguel-Hidalgo JJ, Wang Z, Kyle PB, Hasler G, et al. Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol Psychiatry. 28) Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of atrocytomas in tuberous sclerosis complex. Ann Neurol.2006 Mar; 59(3):490-8. 29) Garzya G, Corallo D, Fiore A, Lecciso G, Petrelli G, Zotti C. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res. 1990; 16(2):101-6. 30) Hashimoto K, Tsukada H, Nishiyama S, Fukumoto D, Kakiuchi T, Shimizu E, Iyo M. Effects of N-acetyl-Lcysteine on the reduction of brain dopamine transpoters in monkey treated with methamphetamine. Ann N Y Acad Sci. 2004 Oct; 1025; 231-5. 31) Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry. 2007; 62 (11):1310-6. 32) Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci. 20013 Aug; 263(5):367- 377. 33) Hoetzel A, Schmidt R. regulatory role of Anesthetic on hemo-oxigenasa 1. Curr. Drug. Targets. 2010; 11:1495-1503. 34) Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci 2007; 27:11496-11500. 35) Ibrahim L, Diazgranados N, Jolkovsky L, Brutsche N, Luckenbaugh D, Herring J. A randomized, placebocontrolled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatmentresistant major depressive disordel. J. Clin Psychopharmacol. 2012; 32:551-557. 36) Jernigan CS, Goswami DB, Austin MC, Iyo AH, Chandran A, Stockmeier CA, Karolewicz B. The mTOR signaling pathway in the prefrontal cortex is compromised in mayor depressive disorder. Progress in Neuro- Psychopharmacology & Biological Psychiatry. 2011; 35:1774-1779. 37) John CS, Smith KL, Van’t Veer A, Gompf HS, Carlezon WAJr, Cohen BM, et al. Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. Neuropsychopharmacology. 2012; 37:2467-2475. 38) Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R, Malafosse A. Alteration in kinase activity but not in protein levels of protein kinase B and glycongen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol. Psychiatry. 2007; 61:240-245. 39) Kavalali ET, Monteggia LM. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry 2012; 169:1150-1156. 40) Klodzinska A, Tatarczynska E, Chojnaka-Wojcik E, Novak G, Cosford ND, Pilc A. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neurropharmacology. 2004 Dec; 47(7):1115. 41) Kotermanski SE, Wood JT, Johnson JW. Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J. Physiol. 2009 Oct 1; 587(Pt 19):4589-604. 42) Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf. 2005; 28(2): 153-181. 43) Laje G, Lally N, Mathews D, Brutsche R, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C Jr. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry. 2012; 72(11): e27-8. 44) Lan M J, Mc Loughlin G A, Griffin J L, Tsang T M, Huang J T, Yuan P, Manji H, Holmes E, Bahn S. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatry. 2009; 14: 269- 279. 45) Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int. J. Neurpsychopharmacol. 2013 Oct; 16(9): 2111-7. 46) Lapierre YD, Oyewumi LK. Fenobam: Another anxiolitic? Curr Ther Res. 1982; 31:95-101. 47) Lauterdorn JC, Lynch G, Vanderklish P, Arai A and Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci. 2000; 20: 8-21 2000. 48) Lauterdorn JC, Truong GS, Baudry M, Bi X, Lynch G and Gall CM. Chronic elevation of brain-derived neurotrophic factor by ampakines. JPET 2003; 307: 297- 305. 49) Legutko B, Li X, Skolnick P. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology 2001; 40:1019-1027. 50) Lejoyeux M, Lehert P. Alcohol-use disorders and depression: Results from individual patient data metaanalysis of the acamprosate-controlled studies. Alcohol. 2011; 46:61-67. 51) Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman R. mTOR dependent synapse formation underlies the repid antidepressant effects of NMDA antagonists. Science. 2010 August 20; 329(5994): 959-964. 52) Li N, Liu RJ, Dwyer JM, Banasar M, Lee B, Son H, Li XY, Agjajanian GK and Dumand RS. Glutamate-Nmethyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011; 69:754-761. 53) Linck VM, Costa-Campos L, Pilz LK, García CRL, Elisabetsky E. AMPA glutamate receptores mediate the antidepressant-like effects of N-acetylcysteine in the Mouse tail suspension test. Behav. Pharmacol. 2012; 23:171-177 2012. 54) Magalhaes P, Dean O, Bush A, Copolov D, Mahli G, Kohlman K, Jeavons S, Schapkaitz I, Anderson Hunt M, Berk M. N-acetylcysteine for mayor depressive episodes in bipolar disorder. Rev Bras Psychiatr. 2011; 33: 374- 378. 55) Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK. Physiological antagonism between 5 hydroxytryptamine 2 A receptor and Group II metabotropic glutamate receptors in prefrontal cortex. JPET. 2000 vol. 292 nº 1:76-87. 28 // EDITORIAL SCIENS
Psicofarmacología 14:86, Junio2014 56) Martin A, Heyes MP, Salazar AM, Law WA, Williams J. Impaired motor skill learning, slowed reaction time, and elevated cerebrospinal fluid quinolinic acid in a sub-group of HIV-infected individuals. Neuropsychology. 1993; 7:147-149. 57) Mezler M, Geneste H, Gault L, Marek GJ. LY- 2140023, a prodrug of the group II metabotropic glutamate receptor agonista LY-404039 for the potencial treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul; 11(7): 833-45. 58) Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neuro-transmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and congnitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17:2921-2927. 59) Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P, Traynelis SF, Dingledine R. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat. Neurosci. 1998 Dec; 1(8): 659-67. 60) Murrough JW, Perez A, Pillemer S, Stern J, Parides MK, aan het Tor M, Collins KA, Mathew SJ, Charney D, Iosifescu DV. Rapid and longer-term antidepressant effects of repeated Ketamine infusions in treatmentresistant-major-depression. Biol Psychiatry. 2013 b; 74(4):250-256. 61) Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST. Fragile X mental retardation proteína deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci USA. 2007 Sep 25; 104(39): 15537-42. 62) Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science. 1992; 258:597-603. 63) Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F, et al. L-acetyl carnitina causes rapid antidepressant effects trough the epigenetic induction of mGlu2 receptors. PNAS 2013; 110 Nº 12: 4804-4809. 64) Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Ann Rev. Pharmacol Toxicol. 2010.;50:295-322. 65) Nowak G, Siwek M, Dudek D, Ziwba A, Pilc A. Effect of zinc supplementation on antidepressant therapy in unipolar depression: A preliminary placebo –controlled study. Pol. J. Pharmacol. 2003; 55:1143- 1147. 66) Ohishi H, Shigemoto R, Nakanishi S, Misuno N,. Distribution of the mRNA for a metabotropic glutamate receptor (mgluR3) in the rat brian: an in situ hybridization study. J Comp Neurol. 1993; 335:252-66. 67) Palucha A, Klak K, Branski P, Putten H, Flor P, Pilc A. Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology (Berl). 2007; 194:555-562. 68) Palucha-Poniewiera A, Pilc A. A selective mGlu7 receptor antagonista MMPIP reversed antidepressantlike effects of AMN082 in rats. Behav Brain Res. 2013; 238:109-112. 69) Pilc J, Wieronsaka JM, Skolnick P. Glutamate-Base Antidepressants: Preclinical Psychopharmacology. Biol. Psychiatry 2013; 73:1125-1132. 70) Porter RH, Jaeschke G, Spooren W, Ballard TM, Buttelmann B, Kolczewski S, et al. Fenobam: A clinically validated non-benzodiazepine anxiolitic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther. 2005; 315:711-721. 71) Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in Treatment Resistant Depression. Biol Psychiatry. 2009; 66(5):522-526. 72) Preskorn S, Baker B, Kolluri S, Menitti F S, Krams M, Landen J M. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP- 101606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 2008; 28:631-637. 73) Preskorn S, Macaluso M, Kurian B. GLYX-13, an NMDA receptor functional partial agonist, reduced depression score without psychotomimetic effects in subjets with major depression disorder who failed another antidepressant agent during the current episode. Poster 5157. Annual Meeting of the American College of Neuropsychopharmacology (ACNP). 2012 December 2-6. Hollywood. Florida. 74) Rajkowska G, Miguel-Hidalgo SJ, Wei J, Dilley G, Pittman SD, Meztler HY, Overholser JC, Roth BL, Stockmeier CA. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry 1999; 45:1085-1098. 75) Raugth B, Peiretti F, Gingras AC, Livingstone M, Shahbazian D, Mayeur GL, et al. Phosphoriyation of eukaryotic translation initiation factor 4BSer422 is modulated by S6 kinases. EMBO J 2004; 23:1761-9. 76) Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE. Et al. Beta-lactam antibiotics offer neuroprotecction by increasing glutamate transporter expression. Nature. 2005; 433:73-77. 77) Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007; 61:822-825. 78) Sanacora G, Zarate C A, Krystal J H, Manji H K. Targeting the glutamatérgica system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008; 7: 467-437. 79) Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF et al. Prolonged rapamycin treatment inhibits mTORc2 assembly and Akt/PKB. Mol Cell 2006; 22:159-168. 80) Scaccianoce S, Matrisciano F, Del Bianco P, Caricasole A, Di Giorgi Gerevini V, Capuccio I, Melchiorri D, Battaglia G, Nicoletti F. Endogenous activation of Group-II metabotropic glutamate receptors inhibits the hypotalamic-pituitary-adrenocortical axis. Neuropharmacology. 2003; 44:555-561. 81) Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, Lim KO. Augmentation of response ande remission to serial intravenous subanesthetic Ketamine in treatment-resistant-depression. J of Affective disorders. 2014;155:123-129. 82) Siwek M, Dudek D, Paul IA, Sowa-Kucma M, Zieba A, Popik P, et al. Zinc supplementation augment afficacy of imipramine in treatment resistant patients: A double blind, placebo-controlled study. J. Affect. Disord. 2009; 118:187-195. 83) Siwek M, Dudek D, Paul IA, Sowa-Kucma M, Zieba A, Popik P, et al. Zinc supplementation augment afficacy of imipramine in treatment resistant patients: A double blind, placebo-controlled study. J. Affect. Disord. 2009; 118:187-195. 84) Steiner J, Walter M, Gos T, Guillemin GI, Bernstein HG, Sarnyai Z, Mawrin C, Brish R, Bielau H, Meyer zu Schnabedissen, Bogerts B and Myint AM. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatérgica neurotransmission. J of Neuroinflammation.2011;8:94. 85) Sukoff Rizzo SJ, Leonard SK, Gilbert A, Dollings P, Smith DL, Zhang MY, et al. The mGluR7 allosteric modulator AMN082: A monoaminergic agent in disguise? J Pharmacol Exp Ther. 2011; 338:345-352. 86) Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R. Potential anxiolitic and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 2001; 132:1423-30. 87) Tizabi Y, Bhatti BH, Manaye KF, Das JR, Akinfiresoye L. Antidepressant-like effects of low kwtamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar- Kyoto rats. Neuroscience 2012; 213:72-80. 88) Trullas R. Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990. 185:1-10. 89) Valentine GW, Mason GF, Gómez R, Fasula M, Watzl J, Pittman B, Krystal JM, Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by (1)H-MRS. Psychiatry Res. 2011 Feb 28; 191(2):122-7. 90) Vyas A, Mitra R, Shankaranayana Rao BS, Chattarji S. Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amigdaloid neurons. J. Neurosci. 2002;22:6810-6818. 91) Watkins JC. I-Glutamate as a central neurotransmitter: looking back. Biochem Soc Trans 2000; 28(4):297-309. 92) Welters ID, Hafer G, Menzebach A, Muhlings J, Neuhauser C, Browning P et al. Ketamine inhibits transcription factor protein 1 and nuclear factor kappa B, interleukin 8 production, as well as CD 11b and CD 16 expression: Studies in human leukocytes and leukocytic cell lines. Anesth. Analg. 2010; 110:934-941. 93) Wieronska JM, Pilc A. Metabotropic glutamate receptors in the tripartite synapse as a target for nex psychotropic drugs. Neeurochem. Int. 2009; 55:85- 97. 94) Zanardi R, Smeraldi E. A double-blind, randomized-controlled clinical trial of acetyl-L-carnitne vs. amisulpride in the treatment of dysthymia. Eur Neuropsichopharmacol. 2006 May; 16(4):281-7. 95) Zarate CA, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, et al. An open-label trial of riluzole in patients with treatment-resistant mayor depression. Am J Psychiatry. 2004; 161:171-174. 96) Zarate CA Jr., Quiroz JA, Singh JB, Denikoff KD, De jesus G, Luckenbaugh DA, Charney DS, Manji HK. An open-label trial of the glutamate-modulating agent riluzole in combination with litium for the treatment of bipolar depression. Biol Psychiatry. 2005 Feb 15; 57(4): 430-2. 97) Zárate C Jr, Sing JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant-major depression. Arch Gen Psychiatry. 2006 Aug; 63(8):856-64. 98) Zarate CA, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am. J. Psychiatry. 2006; 163:153- 155. 99) Zarate C Jr, Brutsche NE, Ibrahim L, Franco- Chaves J, Diaz Granados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA. Replication of Ketamine’s antidepressant efficacy in bipolar depression: A randomized-controlled ad-on-trial. Biol Psychiatry. 2012 Jun 1; 71(11):939-46. 100) Zarate CA Jr, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA, Luckenbaugh DA. A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol Psychiatry. 2013 Aug 15; 74(4):257-64. EDITORIAL SCIENS // 29
